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Abstract ϭ
Objectives: The stentgrafts used for endovascular abdominal aortic repair (EVAR) profited Ϯ
from many technological changes since their appearance. The objective of this study was to ϯ
compare the medium-term results of the 2nd and 3rd generation stentgrafts. ϰ
Material and methods: Three hundred thirty-four patients treated by EVAR between 2005 ϱ
and 2013 were included in this retrospective study. Demographic, anatomical, perioperative ϲ
and follow-up data were collected in a prospective way in an electronic database and ϳ
compared between two groups. The preoperative angio-CTs were all analyzed in depth on a ϴ
suitable 3D work station. Group 1 (n=219) represented the patients treated by 2nd generation ϵ
stentgrafts (Medtronic Talent®, Cook Medical Zenith Flex®, Vascutek-Terumo Anaconda®, ϭϬ
Gore Excluder low-porosity®) and group 2 (n=115) represented the patients treated with 3rdϭϭ
generation stentgrafts (Medtronic Enduring I and II®, Cook Medical Zenith LP®, Gore ϭϮ
Excluder C3®). ϭϯ
Results: The mean follow-up was 42.4 ± 26.8 months with a longer duration in group 1 (52.4 ϭϰ
± 27.2 months vs 23.2 ± 10.9 months, p<.0001). The patients of group 2 had significantly ϭϱ
more risk factors and cardiovascular comorbidities (coronary disease, tobacco addiction, ϭϲ
dyslipidemia, peripheral arterial disease, chronic renal insufficiency). Anatomical ϭϳ
characteristics were similar in the two groups, in particular regarding the iliac arteries which ϭϴ
were significantly more calcified and had a smaller diameter in group 2. The rate of ϭϵ
peroperative complications was similar in the two groups, in particular for complications ϮϬ
related to the iliac axes (3.7% vs 2.6%, p=.96). During the follow-up there was no significant Ϯϭ
difference between the two groups in the rates of survival, reinterventions, or endoleaks and ϮϮ
the progression of the aneurysmal sac. Ϯϯ
Conclusion: This study shows that 3rd generation stentgrafts allow results comparable with Ϯϰ
those of the 2nd generation stentgrafts in spite of more complex iliac anatomies. These results Ϯϱ
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make it possible to expand the indications of EVAR to patients presenting more ϭ
cardiovascular comorbidities without increasing the risk of complications in the short and Ϯ
medium term. ϯ
INTRODUCTIONϰ
Current stentgrafts benefited from technological changes compared to those implanted in the ϱ
first randomized trials. Each industrial company developed a stentgraft whose evolutions with ϲ
each generation were focused on the delivery system, the design of the graft, or the system of ϳ
anchoring. For most of the companies, 3rd generation stentgrafts are now implanted. Some of ϴ
these evolutions can be easily apprehended at the time of the procedure, such as the ϵ
simplification of the delivery system, but the impact or other changes on the long term results ϭϬ
of EVAR may be more difficult to measure. Notwithstanding, these changes coincide with an ϭϭ
improvement of the results of the EVAR in comparison with the first randomized trials(1) and ϭϮ
with a reduction in the rate of explantation over the time(2). These improvements are probably ϭϯ
multifactorial (learning curve, better selection of the patients) but it is interesting to assess ϭϰ
how the new devices contribute to these results and if the technological changes are really ϭϱ
correlated with an improvement of the results of EVAR. ϭϲ
Several studies showed that 2nd generation stentgrafts made it possible to obtain better ϭϳ
long-term results than 1st generation devices (3-5). Although several non-comparative studies ϭϴ
on 3rd generation aortic stentgrafts showed good performances(6-13) only one very recent study ϭϵ
compared this latest generation of grafts with the preceding one (14). This study compared a ϮϬ
new stentgraft manufactured by a single company with results which did not allow concluding Ϯϭ
to major differences between the two generations of devices. It was thus necessary to evaluate ϮϮ
other stentgrafts to confirm or not these results in order and determine the actual benefits Ϯϯ
obtained with this new generation of stentgrafts. The objective of this study was to compare Ϯϰ
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the mid-term results of 2nd and 3rd generation stentgraft in the treatment of infrarenal ϭ
abdominal aortic aneurysms (AAA). Ϯ
MATERIAL AND METHODSϯ
Starting from a prospective institutional register beginning in January 2000, all the patients ϰ
operated on for infrarenal AAA by EVAR with a 2nd or 3rd generation stentgraft were included ϱ
retrospectively in this study. The patients treated with first generation or fenestrated or ϲ
branched stentgrafts were excluded, as well as the patients operated on for fissured or ϳ
ruptured AAA. In order to compare preoperative vascular anatomies, only the patients having ϴ
a preoperative angio-CT analyzable on a work station were included. The patients included in ϵ
this study were operated between January 2005 and December 2013.   ϭϬ
Implanted stentgrafts and design of the study groups.The stentgrafts implanted over the ϭϭ
period of the study were Talent®, Enduring® I and II (Word medical-Medtronic, Sunrise, FL, ϭϮ
USA), Zenith Flex® and Zenith LP® (William Cook Europe, Biaeverskow, Denmark), ϭϯ
Excluder® (Low Permeability 2nd generation and 3rd generation with C3 delivery system) ϭϰ
(WL Gore, Flagstaff, AZ, USA), and Anaconda® (Sulzer-Vascutek, Inchinnan, Renfrewshire, ϭϱ
Scotland). Two groups were designed considering the specific technological changes of each ϭϲ
company. Group 1 represented the 2nd generation stentgrafts, including Talent® (Medtronic), ϭϳ
Zenith Flex® (Cook), Excluder low-permeability® (Gore), and Anaconda® (Vascutek). ϭϴ
Group 2 represented the 3rd generation stentgrafts, including Endurant® I and II (Medtronic), ϭϵ
LP Zenith® (Cook) and Excluder® C3 (Gore). ϮϬ
Preoperative clinical and anatomical data. For each patient, the cardiovascular risk factors Ϯϭ
and the comorbidities were collected (Table I). All the patients were explored by an ϮϮ
abdominopelvic preoperative angio-CT with injection of contrast and millimetric cuts. The Ϯϯ
preoperative anatomical morphological criteria were analyzed with the EndoSize software (15)Ϯϰ
(Therenva, Rennes, France). Besides the diameters and working lengths for the choice of the Ϯϱ
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stentgraft, measurements “for research” were collected because their influence on the onset of ϭ
a complication during follow up could be addressed (16). The usual quantitative parameters Ϯ
measured for the choice of the stentgraft are summarized in table II and the qualitative ϯ
parameters “for research” are listed in table III. All the anatomical parameters were described ϰ
with continuous measurements apart from measurements of calcifications and thrombi which ϱ
were categorized according to a grade of severity (16) ranging from 0 to 3. Grade 0 ϲ
corresponded to calcifications or of thrombi between 0 and < 25% of the arterial ϳ
circumference, grade 1 between 25 and < 50%, grade 2 between 50 and < 75% and grade 3 ϴ
75%. Aortic neck was regarded as conical if the diameter 15 mm below the lowest renal artery ϵ
increased by more than 10% compared to the proximal diameter (17).ϭϬ
Peroperative data. During the procedure, the following data were collected: mark and model ϭϭ
of stentgraft, the type of femoral access (open or percutaneous), the total duration of the ϭϮ
intervention, the parameters of irradiation and the volume of product of contrast used. ϭϯ
Peroperative complications were classified as complications related to the accesses, ϭϰ
complications related to the iliac axes (dissection or wound), and complications related to the ϭϱ
stentgraft.ϭϲ
Early postoperative data (<30 days). The complications were classified as complications of ϭϳ
vital functions (cardiac, renal, neurological…) and complications related to the stentgraft ϭϴ
(endoleaks, thrombosis…). The complications were also grouped into two categories: major ϭϵ
and minor complications. Complications requiring reoperation or with a short term life-ϮϬ
threatening forecast were also considered as major, as those with irreversible sequelae. Ϯϭ
Primary technical success and secondary technical success were defined according to the ϮϮ
international standards (18).  Ϯϯ
Follow up data. The usual follow-up of the patients was angio-CT one, six, 12 and 24 months Ϯϰ
after the intervention. Beyond two years, the methods and the rhythm of monitoring were Ϯϱ
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adapted to the evolutionary process of the aneurysmal sac, the presence or not of an endoleak ϭ
and the patient’s overall condition (19). Endoleaks were classified according to the Ϯ
international standards (18). ϯ
Statistical analysis. Quantitative data are presented as mean ± standard deviation (SD) and ϰ
qualitative data as counts and percentages. Quantitative variables were compared by the ϱ
Student t test and qualitative variables by the chi-square test. Follow-up data were analyzed ϲ
with actuarial curves according to the Kaplan-Meier method and were compared using a Log-ϳ
rank test. XLStats® software (ADDINSOFT, Paris, France) was used for the realization of the ϴ
statistical analysis. The significance threshold was set at 0.05.  ϵ
RESULTSϭϬ
Three hundred thirty-four patients (668 iliac) were included in this study. Two hundred and ϭϭ
nineteen patients (65.6%) (438 iliac) were assigned to group 1 and 115 (230 iliac) to group 2. ϭϮ
The distribution of the different types of stentgrafts in each group is presented on Figs. 1 and ϭϯ
2. ϭϰ
Preoperative clinical data (Table I). The mean age of the patients was 74.7 ± 8.2 years in ϭϱ
group 1 and 74.7 ± 8.8 years in group 2 (p= 0.98). In univariate analysis, among all the ϭϲ
studied characteristics, five were significantly different. There were more patients with a ϭϳ
history of smoking in group 2 than in group 1 (91.3% vs 76.7%, p=0.002). There were more ϭϴ
patients with a history of dyslipidemia in group 2 than in group 1 (83.5% vs 72.1%, p=0.03). ϭϵ
There were more patients with coronary disease in group 2 than in group 1 (75.7% vs 50.2%, ϮϬ
p<0.0001). There were more patients with chronic renal insufficiency in group 2 than in group Ϯϭ
1 (36.5% vs 6.8%, p<0.0001). Lastly, there were more patients with peripheral occlusive ϮϮ
arterial disease in group 2 than in group 1 (17.4% vs 5.9%, p=0.002). Ϯϯ
Anatomical data (Tables II and III). Three quantitative characteristics presented a significant Ϯϰ
difference between the two groups. The diameter of the end of the common iliac arteries was Ϯϱ
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significantly smaller in group 2 than in group 1 (13.9 ± 3.7 mm vs 15.3 ± 3.9 mm, p<0.0001). ϭ
The smallest diameter of the external iliac arteries was smaller in group 2 (7.4 ± 1.6 mm vs Ϯ
8.3 ± 1.9 mm, p<0.0001). The diameter of the celiac aorta was smaller in group 2 (26.9 ± 3.4 ϯ
mm vs 27.7 ± 2.8 mm, p=0.04). The maximum diameter of the aneurysm tended to be larger ϰ
in group 2 (58.6 ± 11.9 mm vs 56.14 ± 10.2 mm, p=0.051). Among the qualitative ϱ
characteristics of the sizing three of them differed between the 2 groups. Iliac calcifications ϲ
were more important in group 2 than in group 1 (11.7% grade 3 in group 2 vs 2.5% grade 3 in ϳ
group 1, p<0.0001). There were more conical aortic necks in group 2 (24.8% vs 13.3%, ϴ
p=0.04). Lastly, there were more internal iliac thromboses in group 2 (6.6% vs 2.3%, p=0.01). ϵ
Preoperative data. The duration of operation was significantly longer and the volume of ϭϬ
injected contrast product was significantly higher in group 1 than in 2. The proportion of ϭϭ
percutaneous accesses was significantly greater in group 2 (Table IV). There was no ϭϮ
significant difference between the two groups with regard to the complications related to the ϭϯ
accesses (n=7, 3.2% in group 1 vs n=2, 1.7% in group 2, p=0.43), those related to the iliac ϭϰ
axes (n=8, 3.7% in group 1 vs n=3, 2.6% in group 2, p=0.61) and those related to the ϭϱ
stentgrafts (n=30, 13.7% in group 1 vs n=16, 13.9% in group 2, p=0.96). Overall there were ϭϲ
three (1.4%) failures of introduction of the stentgraft (one introduction from the side opposite ϭϳ
to the operative plan) in group 1 and none in group 2 (p=0.21), without any failure on both ϭϴ
sides in the two groups. There was one conversion into open surgery in each group (0.5% in ϭϵ
group 1 and 0.9% in group 2, p=0.64). In group 1 the cause of conversion was a failure of ϮϬ
deployment and in group 2 it was due to an attempt to correct a proximal endoleak with an Ϯϭ
aortic extension which was deployed in the meshes of the supra-renal stent. In each group ϮϮ
there was one (0.5% in group 1 vs 0.9% in group 2) unplanned coverage of an internal iliac Ϯϯ
artery (p=0.64). During the procedures, there were four (1.8%) complications at the time of Ϯϰ
the deployment of the stentgraft in group 1 and five (4.3%) in group 2 (p=0.18), and two Ϯϱ
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stenoses or plications of prosthetic limbs in each group (0.9% in group 1 and 1.7% in group, ϭ
p=0.51). The four stenoses or plications were treated by angioplasty with stenting. Ϯ
Immediate postoperative data (<30 days). The mean duration of hospitalization was 8.3 ± 9 ϯ
days in group 1 and 7.9 ± 2.3 days in group 2 (p=0.68). Mortality rates at 30 days was similar ϰ
in the two groups (n=4, 1.8% in group 1 vs n=2, 1.7% in group 2, p=0.95). No significant ϱ
difference was found in the rate of major complication postoperative (n=17, 7.8% in group 1 ϲ
vs n=12, 10.4% in group 2, p=0.41). The primary and secondary technical success rates were ϳ
89.5% and 96.8% in group 1 and 87.8% and 97,4% in group 2 (p= 0.64 and 0.76, ϴ
respectively). ϵ
Follow up.The mean duration of clinical follow-up was 42.4 ± 26.8 months (52.4 ± 27.2 ϭϬ
months in group 1 and 23.2 ± 10.9 months in group 2 (p<0.0001)).ϭϭ
Survival. Survival rates at 1, 2 and 3 years were 94.5 ± 1,6%, 87.4 ± 2.3% and 82.0 ± 2.7% in ϭϮ
group 1 and 89.5 ± 2.9%, 80.6 ± 4.2% and 75.0 ± 5.0% in group 2, respectively (p=0.07) (Fig. ϭϯ
3). The aneurysm-related death rate at 3 years was 3.3 ± 1.2% (n=7) in group 1 and 4.9 ± ϭϰ
2.2% (n=5) in group 2 (p =0.44). The rate of aneurysmal rupture at 3 years was 0.52% (n=1) ϭϱ
in group 1 and 1.28% (n=1) in group 2 (p=0.33). All the patients presenting a rupture died. ϭϲ
Evolution of the aneurysmal sac. At 3 years, the rate of regression of the aneurysmal sac was ϭϳ
48.9 ± 3.6% in group 1 and 52.6 ± 5.6% in group 2 (p=0.09). Conversely, the growth rate of ϭϴ
the aneurysmal sac at 3 years was 18.7 ± 2.8% in group 1 and of 13.1 ± 6.9% in group 2 ϭϵ
(p=0.13). ϮϬ
Endoleaks. Table V summarizes the endoleaks at three years. Whatever type of endoleak, Ϯϭ
there was no difference between the groups.  ϮϮ
Reinterventions. Including all reinterventions, there was no difference at three years between Ϯϯ
the groups (fig. 4). The rates of survival without reintervention for endoleak were 85.6 ± 2.5% Ϯϰ
in group 1 and of 94.0 ± 2.7% in group 2 at 3 years, respectively (p=0.11). The rates of Ϯϱ
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prosthetic limb thrombosis at three years were 5.8 ± 1.6% in group 1 and 8.1 ± 2.9% in group ϭ
2, respectively (p=0.43) with the need for a crossover femoro-femoral bypass in all the Ϯ
patients except one who was treated medically. One patient of group 1 (0.5%) and two (1.8%) ϯ
of group 2 required further surgery for intestinal ischemia without significant difference at ϰ
three years (p=0.24). The rates of reintervention for limb stenosis and/or plication were not ϱ
statistically different between the 2 groups, reaching 3.1 ± 2.2% in group 1 and 1.4 ± 0.8% in ϲ
group 2 at three years (p=0.65). At three years, five patients of group 1 (2.3%) were ϳ
reoperated on for explantation of the stentgraft whereas no patient of group 2 had to be ϴ
explanted (p=0.43). The causes of conversion into open surgery were one type IA endoleak at ϵ
35 months without possibility of endovascular treatment with a proximal or fenestrated ϭϬ
extension, three type II endoleaks with a diameter increase of more than 10 mm (all at 36 ϭϭ
months) and one infection at 24 months. ϭϮ
Analyzes by stentgraft. The comparison between the Medtronic devices (largest group of ϭϯ
patients in this study) showed a lower rate of survival at three years for the last generation ϭϰ
devices (80 ± 3.7% in group 1.70 ± 6.4% in group 2, respectively, p = 0.02). There was no ϭϱ
difference concerning the rates of rupture, aneurysm-related death, prosthetic limb ϭϲ
thrombosis, survival without reintervention, conversion into open surgery, and reintervention ϭϳ
whatever the cause. Contrary to type IA and IB endoleaks, there was a difference in the rate of ϭϴ
type II endoleaks in favor of the new generation devices (28.3 ± 4.5% in group 1 vs 10.9 ± ϭϵ
3.7% in group 2), leading to a tendency a reduced number of patients without reintervention ϮϬ
for endoleak in group 1 (82.7 ± 3,7% in group 1 vs 95.1 ± 2.8% in group 2, respectively, p= Ϯϭ
0.06). Growth rate was 27 ± 4.4% in group 1 and 16.2 ± 11.4% in group 2 (p=0.01). The rate ϮϮ
of regression was 39 ± 4.9% in group 1, and 50.6 ± 6.8% in group 2 (p=0.005). In this Ϯϯ
subgroup, the risk factors were also more severe in the group receiving a new generation Ϯϰ
stentgraft with higher rates of smoking addiction (88.8% vs 70.8%, p=0.005), PAOD (20% vs Ϯϱ
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3.2%, p=0.0005), severe chronic renal insufficiency (28.8% vs 4%, p<0.0001) and coronary ϭ
disease (73.7% vs 47%, p=0.0002). Ϯ
DISCUSSION ϯ
The analysis of the preoperative demographic data of our study explains at least in part the ϰ
difference observed in the preoperative anatomical data. In group 2, the patients had more ϱ
cardiovascular comorbidities and risk factors, which can explain the higher proportion of ϲ
peripheral vascular disease in group 2. Therefore it looks logical that the anatomy of iliac ϳ
arteries is more complex in terms of calcifications and stenoses in this group. Obviously, this ϴ
is a selection bias since the patients of this group received stentgrafts of the last generation.ϵ
The analysis of the peroperative data showed a significant reduction in the total ϭϬ
duration of the procedure (p=0.04) without any reduction in the duration of fluoroscopy or of ϭϭ
the amount of irradiation. The more frequent use of a closure system in group 2 can explain ϭϮ
this result in part because at least one study showed a reduction in the duration of procedures ϭϯ
with the use of a closure system (20). The volume of product of contrast was also significantly ϭϰ
reduced. The learning curve of the operators and the planning of the incidences of ϭϱ
angiography thanks to sizing software after 2010 probably made it possible to reduce the ϭϲ
number of injections. The higher proportion of patients with chronic renal insufficiency also ϭϳ
obliged us to take better precautions regarding the volume of product of contrast injected. ϭϴ
Lastly, the performance of some procedures in a hybrid room with image fusion since 2012 ϭϵ
could also contribute to this reduction.  ϮϬ
In our study, there were not more iliac complications in group 2 in spite of more iliac Ϯϭ
complex anatomies, which was expected due to the reduction in the profiles of the stentgrafts. ϮϮ
Therefore, low profile stentgrafts of 3rd generation seem to be reliable, making it possible to Ϯϯ
treat more complex anatomies without increasing the perioperative morbi-mortality. Ϯϰ
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The results of our study regarding follow-up data did not show a significant difference ϭ
between the two groups with regard to survival, reinterventions, endoleaks and the evolution Ϯ
of the aneurysmal sac. Growth rates of the aneurysmal sac observed in our study can appear ϯ
high (18.7% in group 1 and 13.1% in group 2), but they are in fact comparable with the data ϰ
of the literature reporting growth rates between 17% at three years and 41% at five years in ϱ
the meta-analysis of Schanzer et al.(17). In the study of Mertens et al.(21) the growth rate at five ϲ
years was 17.5% and in the study of Walker et al.(22), it was 21.4% at three years. ϳ
Except for the improvement of the profile of the delivery system making it possible to ϴ
navigate in complex iliac anatomies, the technological changes between 2nd and 3rd ϵ
generation do not constitute a major change in the concept and the architecture of stentgrafts ϭϬ
(improvement of the fineness of the fabric, modification of the material or of the structure of ϭϭ
the stents), and it is difficult to determine in what these evolutions could have improved to a ϭϮ
significant degree mid-term results in particular regarding the rates of endoleaks.  ϭϯ
For this study we chose to distribute the different types of stentgrafts in two groups. ϭϰ
Four types of stentgrafts were proposed by Medtronic: Aneurx®, Talent® (2005), Enduring®ϭϱ
I (2011) and II (2012). The first generation stentgraft (Aneurx®) was excluded from this ϭϲ
study. Talent® was thus classified in group 1 (2nd generation). The main developments ϭϳ
between Talent® and Enduring® were the addition of hooks positioned at the level of the ϭϴ
supra-renal stent, the removal of the lateral reinforcement bar, and the reduction in the profile ϭϵ
of the delivery system. We chose to gather up Enduring® I and II in group 2 (3rd generation) ϮϬ
because the structural differences were much less prominent than between Talent® and Ϯϭ
Enduring® I. The addition of radioopaque markers and the reduction in the diameter of the ϮϮ
delivery system for some diameters of main bodies constitute the principal differences Ϯϯ
between the two models of Enduring®. It is important to note that the sub-group analysis for Ϯϰ
this company found different results in the follow-up data which were not found in the initial Ϯϱ
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tracking cohort. These results relate to the total survival at three years which was lower in ϭ
group 2 and a better rate of type II endoleaks in the same group. These results are explained in Ϯ
part because of the preoperative demographic factors. Indeed the patients had a stronger ϯ
history a tobacco addiction. Patients were thus more exposed to complications related to this ϰ
risk factor of cardiovascular morbi-mortality but also to the risk of cancer, which may have ϱ
contributed to the lower survival. As to the lower rate of type II endoleaks, it was reported in ϲ
several publications (23-25) that tobacco had paradoxically a protective effect on the occurrence ϳ
of type II endoleaks, probably through the prothrombogenic effect of tobacco. While this was ϴ
not always found in the other studies, the higher frequency of type II endoleaks can explain ϵ
the higher rates of reintervention for endoleak and aneurysmal growth in group 1, and on the ϭϬ
opposite a higher rate of aneurysmal sac shrinkage in group 2. The presence of an important ϭϭ
difference in the population in this subgroup makes it difficult to conclude that the new ϭϮ
generation stentgrafts are better. However, these results at least consolidate the data of ϭϯ
equivalence between the two generations of stentgrafts with broader anatomical eligibility ϭϰ
criteria. In order to neutralize these demographic differences the application of a propensity ϭϱ
score would be interesting, but it requires a thorough statistical analysis which could be the ϭϲ
subject of additional studies. ϭϳ
As regards the Cook stentgrafts, the distribution of Zenith Flex® in group 1 and Zenith ϭϴ
LP® in group 2 was already used in the study of Sobocinski et al. (14). The main changes ϭϵ
between these two models were a longer proximal non covered stent and a finer polyester ϮϬ
fabric in Zenith LP®. The material of the stents also changed from stainless steel to nitinol Ϯϭ
with a lower profile of the delivery system of the bifurcated modules. Concerning Gore ϮϮ
stentgrafts, the first generation of Excluder® was made available in 1997, the Low Ϯϯ
Permeability appeared in 2004, and the 3rd generation with the C3 Delivery System appeared Ϯϰ
in 2010. As for Aneurx®, the first generation Excluder® was excluded from the study, and Ϯϱ
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none of this type of stentgraft was implanted out in our institution. Gore Excluder Low ϭ
Permeability® was thus classified in group 1 and Gore Excluder C3 Delivery System® in Ϯ
group 2. The principal differences between these two models were initially the introduction of ϯ
the repositioning system and also the reduction in the profile of the delivery system of the ϰ
main body and the extensions. Lastly, for the Vascutek-Terumo stentgrafts, three models were ϱ
marketed. BluGlide™ and ONE-LOK™ are the two last generations and we only used the ϲ
first one, which was classified in group 1. ϳ
Studies had already shown the superiority of the 2nd generation stentgrafts. The study ϴ
of Verzini et al.(5) showed significantly better long-term results in terms of explantations, ϵ
reinterventions, and growth of the aneurysmal sac at seven years. This monocentric study ϭϬ
concerned 1412 patients and reported longer-term results (five and seven years) that our ϭϭ
study. However, the composition of the groups was different, with the grouping of AneurX®ϭϮ
and Talent® in the older generation group and the grouping of the Zenith® and Endurant® in ϭϯ
the newer generation group. This composition of the groups is open to discussion since 1st and ϭϰ
2nd generation stentgrafts of the same company were included in the same group. Other ϭϱ
studies already showed better results for Talent® when compared to Aneurx® (26, 27). ϭϲ
Consequently the comparison with Zenith® and Endurant® is biased and makes the results of ϭϳ
this study more difficult to interpret. In our study we compared stentgrafts of similar ϭϴ
generation with comparable results between the different stentgrafts of each group (28). Ouriel ϭϵ
et al.(26) reported a series of 703 patients comparing five different first generation (Ancure®, ϮϬ
original Excluder® and AneurX®) and second generation (Talent® and Zenith Flex®) Ϯϭ
stentgrafts. The principal results of this study were the absence of difference in the rates of ϮϮ
reinterventions at one year, and significantly lower rates of endoleaks at one year for the Ϯϯ
second generation stentgrafts as well a higher rate of aneurysmal sac shrinkage for 2ndϮϰ
generation stentgrafts. This study thus concluded on the superiority of second generation Ϯϱ
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stentgrafts compared to first generation devices. Another study of Wales et al.(28) compared ϭ
the results of 2nd generation stentgrafts in 286 patients receiving Zenith and Talent grafts and Ϯ
did not show a significant difference concerning type 1 or 3 endoleaks, survival without ϯ
reintervention, and survival all causes of death confused at three years. In the Zenith group ϰ
there were significantly higher proportions of short necks and neck angulation > 60°. The ϱ
analysis of the preoperative anatomy did not report qualitative and quantitative measurements ϲ
of iliac accesses. The study of Mensel et al.(29) compared Endurant® and Talent®. This study ϳ
on 71 patients had results only over the first 30 days. The clinical success rate was ϴ
significantly better in the Endurant® group (97.2% vs 80.0%, p=0.028). ϵ
Currently, only one study (14) compared 2nd and 3rd generation with mid-term results. ϭϬ
This study concerned 208 patients receiving stentgrafts of the same company (Cook Zenith ϭϭ
Flex® vs Zenith LP®) which was methodologically more valid, but it excluded inter alia all ϭϮ
the stentgrafts marketed by other companies which reduced the scope of the conclusions on ϭϯ
the results of 3rd generation stentgrafts. Besides the characteristics of the aortic neck, the ϭϰ
analyzed anatomical characteristics in this study were primarily the tortuosity and the minimal ϭϱ
diameter of the iliac arteries. The results of this study were in agreement with ours since it did ϭϲ
not show significant differences at one and two years concerning the rates of survival without ϭϳ
reinterventions and the rates of survival all causes of death confused. The iliac anatomies ϭϴ
were also more complex in the Zenith LP® group with a higher proportion of external iliac ϭϵ
arteries with a diameter < 7 mm. ϮϬ
In addition to its retrospective character and the absence of randomization, a limit of Ϯϭ
this study was the significant difference in the duration of follow-up of the patients between ϮϮ
the groups which prevents from any conclusion on the long-term results. Since last generation Ϯϯ
stentgrafts are implanted since less than five years, it is still too early to obtain long-term data Ϯϰ
beyond five years. The advantage of including several stentgrafts is to get wider conclusions Ϯϱ
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on the benefit brought by the new generation of stentgrafts even if the majority of the ϭ
stentgrafts used were marketed by two firms (Cook and Medtronic), which reflects the current Ϯ
market. The other bias of this study was a rather long period of inclusion which was necessary ϯ
to include a sufficient number of patients in each group and to allow statistically valid ϰ
comparisons. The advantage was to have a long follow-up for many patients, but that could ϱ
integrate more heterogeneous practices regarding the preoperative sizing or the procedure ϲ
than in a study with a shorter inclusion period and a single operator, as reported by Sobocinski ϳ
et al. (14). Lastly, among the many data collected in this study, we did not report the rates of ϴ
stentgraft migration. However migration is a late event in the follow-up of stentgrafts which is ϵ
diagnosed on regular CT-scans. In our institution and in accordance with the ϭϬ
recommendations, long-term duplex ultrasound is the key examination in the absence of ϭϭ
complication detected at the time of the follow-up, and, in the recent studies, migrations ϭϮ
became rare (9, 30).  ϭϯ
CONCLUSION ϭϰ
Third generation stentgrafts made it possible to increase the number of eligible patients for ϭϱ
EVAR with the improvement of the profiles of the stentgrafts, they but did not show their ϭϲ
superiority to 2nd generation stentgrafts in terms of postoperative clinical results and of mid-ϭϳ
term specific complications. The reduction in the profiles of the stentgrafts required ϭϴ
technological changes which require a longer follow-up to determine if the results found in ϭϵ
this study are maintained or not. ϮϬ
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Legend of figures ϭ
Fig. 1. Group 1, 2nd generation stentgrafts. Ϯ
Fig. 2. Group 2, 3rd generation stentgrafts. ϯ
Fig. 3. Kaplan-Meier estimates for total survival at 3 years. ϰ
Fig. 4. Kaplan-Meier estimates for freedom from reintervention at 3 years.ϱ
ϲ
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Table I. Demographic and clinical data 
Total population (n=334) Group 1 
(n=219) 
Group 2 
(n=115) 
P 
Age (years, mean ± SD) 74.7 ± 8.4 74.7 ± 8.2 74.7 ± 8.8 0.98 
Gender (men) 309 (92.5%) 200 (91.3%) 109 (94.8%) 0.25 
Hypertension 258 (77.2%) 166 (75.8%) 92 (80.0%) 0.37 
Dyslipidemia 257 (76.9%) 158 (72.1%) 96 (83.5%) 0.03 
Diabetes 41 (12.3%) 24 (11.0%) 16 (13.9%) 0.47 
Tobacco 273 (81.7%) 168 (76.7%) 105 (91.3%) 0.002 
Coronary disease 197 (59.0%) 110 (50.2%) 87 (75.7%) <0.0001 
Aorto-coronary bypass 36 (10.8%) 26 (11.9%) 10 (8.7%) 0.37 
Aortic valvular replacement 18 (5.4%) 12 (5.5%) 6 (5.2%) 0.92 
Coronary angioplasty 48 (14.4%) 28 (12.8%) 20 (17.4%) 0.25 
Chronic renal insufficiency (GFR<60)* 57 (17.1%) 15 (6.8%) 42 (36.5%) 0.0001 
Chronic respiratory insufficiency 21 (6.3%) 15 (6.8%) 6 (5.2%) 0.53 
Dialysis 4 (1.2%) 2 (0.9%) 2 (1.7%) 0.58 
Peripheral vascular disease 33 (9.9%) 13 (5.9%) 20 (17.4%) 0.002 
Carotid atheroma 25 (7.5%) 15 (6.8%) 10 (8.7%) 0.56
Hemoglobin (g/dL ; mean ±SD) 14.1 ± 1.7 14.1 ± 1.7 14.1 ± 1.7 1 
Creatinine rate (μmol/l ; mean ± SD) 97.6 ± 54.0 95.6 ± 33.4 98.8 ± 63.9 0.72 
FEVG* (% ; moyenne ±DS) 55.0 ± 11.8 56.0 ± 11.4 51.1 ± 13.0 0.06 
* Ventricular ejection fraction 
* Glomerular filtration rate expressed as mL/min/1.73m² according MDRD  
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Table II. Quantitative anatomical data 
* : all the measurements are presented as mean  SD 
Total 
population 
(n=334) 
Group 1 
(n=219) 
Group 2 
(n=115) 
P 
Proximal neck diameter (mm)* 23.5 ± 3.3 23.7 ± 3.2 23.1 ± 3.4 0.13 
Mid neck diameter (mm)* 24.0 ± 3.6 24.1 ± 3.5 23.9 ± 3.7 0.66 
Distal neck diameter (mm)* 24.8 ± 4.0 25.0 ± 4.0 24.5 ± 4.0 0.31 
Neck length (mm)* 27.7 ±  12.7 28.0 ± 12.7 27.0 ± 12.6 0.48 
Common iliac diameter (mm)* 14.8 ± 3.9 15.3 ± 3.9 13.9 ± 3.7 <0.0001 
Aneurysm length (mm)* 110.3 ± 16.7 109.4 ± 16.6 111.8 ± 17.0 0.23 
Common iliac length (mm)* 64.1 ± 17.4 64.1 ± 15.9 64.0 ± 20.1 0.93 
Aortic bifurcation diameter (mm)* 27.2 ± 7.7 26.6 ± 7.5 28.2 ± 7.9 0.07 
Aneurysm maximum diameter (mm)* 57.0 ± 10.9 56.1 ± 10.2 58.6 ± 11.9 0.051 
Celiac trunk diameter (mm)* 27.4 ± 3.0 27.7 ± 2.8 26.9 ± 3.4 0.04 
Aortic neck angulation (°)* 32.0 ± 15.3 31.8 ± 15.5 32.5 ± 15.1 0.68 
Iliac minimum diameter  (mm)* 8.0 ± 1.9 8.3 ± 1.9 7.4 ± 1.6 <0.0001 
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Tableau 1. Table III. Qualitative anatomical data (for research) of the sizing 
   Total 
population 
(n=334) 
Group 1 
(n=219) 
Group 2 (n= 
115) 
P
Iliac calcifications Grade 0 189 (28.3%) 141 (32.2%) 48 (20.9%) 0.0006 
Grade 1 306 (45.8%) 191 (43.6%) 115 (50.0%)
Grade 2 135 (20.2%) 95 (21.7%) 40 (17.4%)
Grade 3 38 (5.7%) 11 (2.5%) 27 (11.7%)
 Aortic neck calcifications Grade 0 191 (57.2%) 128 (58.4%) 63 (54.8%) 0.44
Grade 1 96 (28.7%) 57 (26%) 39 (33.9%) 
Grade 2 41 (12.3%) 30 (13.7%) 11 (9.6%) 
Grade 3 6 (1.8%) 4 (1.8%) 2 (1.7%) 
Neck thrombus Grade 0 179 (53.6%) 115 (52.5%) 64 (55.7%) 0.08
Grade 1 87 (26%) 51 (23.3%) 36 (31.3%)
Grade 2 51 (15.3%) 39 (17.8%) 12 (10.4%)
Grade 3 17 (5.1%) 14 (6.4%) 3 (2.6%)
Shape of the neck Conical 65 (19.5%) 29 (13.2%) 29 (25.2%) 0.04
Aneurysm shape Sacciform 33 (9.9%) 17 (7.8%) 16 (13.9%) 0.07
PAOD Thrombosed 102 (30.5%) 60 (27.4%) 42 (36.5%) 0.08
Internal iliac artery  Thrombosed 25 (3.7%) 10 (2.3%) 15 (6.5%) 0.01
Associated internal iliac aneurysm Yes 12 (1.8%) 6 (1.4%) 6 (2.6%) 0.30
Polar artery Yes 69 (20.7%) 44 (20.1%) 24 (20.9%) 0.83
ǣǤ
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 Table IV. Peroperative data 
Total 
population 
(n=334) 
Group 1 
(n=219) 
Groupe 2 
(n=115) 
P 
Duration of procedure (min. mean ± SD) 181.3 ± 114.6 193.2 ± 70.2 162.9 ± 159.6 0.04 
Contrast product (mL. mean ± SD) 137.1 ± 89.4 181.9 ± 105.4 105.8 ± 59.1 <0.0001 
Duration of fluoroscopy (min. mean ± SD) 20.5 ± 15 19.6 ± 12 21.1 ± 17 0.54 
DAP* (mGy.m². mean ± SD) 6.6 ± 6.9 6.2 ± 5.7 7.0 ± 7.7 0.51 
Percutaneous access (n. (%)) 80 (24%) 30 (13.7%) 50 (43.5%) <0.0001 
*Dose-area product 
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  Table V. Endoleaks occurred during the follow-up 
 Total population 
(n=332) 
Group 1 
(n=218) 
Group 2 
(n=114) 
P 
All types of endoleaks (n. %) 87 (26.2%) 63 (28.9%) 24 (21.1%) 0.37 
Type IA endoleaks (n. %) 11 (3.3%) 10 (4.6%) 1 (0.9%) 0.17 
Type IB endoleaks (n. %) 16 (4.8%) 12 (5.5%) 4 (3.5%) 0.97 
Type II endoleaks (n. %) 64 (19.3%) 46 (21.1%) 18 (15.8%) 0.50 
Type III endoleaks (n. %) 5 (1.5%) 4 (1.8%) 1 (0.9%) 0.58 
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 Months 6 12 18 24 30 36 
Group 1 
(2nd generation) 
N at risk 206 203 199 193 178 170 
Survival (%) 94.9 94.5 92.1 87.4 85.5 82.0 
Standard error (%) 1.5 1.6 1.8 2.3 2,4 2.7 
Group 2 
(3rd generation) 
N at risk 109 103 78 54 33 14 
Survival (%) 94.7 89.5 85.3 80.6 75.3 75.0 
Standard error (%) 2.1 2.9 3.4 4.2 5.0 5.0 
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
 Months 6 12 18 24 30 36
Group 1 
(2nd generation)
N at risk 188 183 170 159 143 135
Survival (%) 88.9 84.5 80.1 78.6 78.6 75.1
Standard error (%) 2.1 2.5 2.7 2.8 2.8 3.1 
Group 2 
(3rd generation)
N at risk 98 91 67 43 25 10
Survival (%) 87.6 86.7 84.1 80.2 80.2 80.2
Standard error (%) 3.1 3.2 3.6 4.4 4.4 4.4 
